Eli Lilly (NYSE:LLY)
says it entered into an agreement with National Institute of Allergy
and Infectious Diseases to study baricitinib as part of the institute’s
Adaptive Covid-19 Treatment Trial.
The study, which will start this month with
results expected in the next two months, “will investigate the efficacy
and safety of baricitinib as a potential treatment for hospitalized
patients diagnosed with Covid-19.”
Baricitinib, which is marketed as Olumiant, is
approved in more than 65 countries to treat adults with moderately to
severely active rheumatoid arthritis
Lilly also says it will advance another drug known
as LY3127804 to Phase 2 testing in “pneumonia patients hospitalized
with Covid-19 who are at a higher risk of progressing to acute
respiratory distress syndrome.”
https://seekingalpha.com/news/3559950-eli-lilly-launches-clinical-testing-of-potential-coronavirus-treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.